162 Potential Diabetes Drug Losing Its Patents

Are you looking to expand your generic drug portfolio or initiate novel research in the diabetes treatment space?

We’ve curated a valuable dataset of diabetes drug patents (like Insulin Glulisine, Glargine, and Lispro) expiring between 2024 and 2028 –  Total 162 including details like:
✅ Applicant Company
✅ Patent Number
✅ Expiration Date
✅ Active Ingredient
✅ Routes of Administration

Download Demo Data Set 

📉 As blockbuster insulin patents like US9827379 from Sanofi approach expiry, there’s a window of opportunity for:
✅ Pharmaceutical companies to develop cost-effective generic versions
✅ Researchers to enhance or modify existing formulations and file new patents
✅ Startups and CROs to explore licensing, research, or strategic development

💼 If you’re a researcher, biotech startup, or pharma manufacturer, this dataset can save months of effort and guide your pipeline or research investment strategy.

📩 Reach out to us for access to our RA data pack or to explore consulting and co-development opportunities.

🔗 Contact: contact@ieearc.com  

Fill out the form to send your query